“Our financial performance reflects our capacity to respond to the medical care needs. Our estimates at the moment indicate total revenue of almost RON750 million, which means about 16% growth in revenue on 2016,” said Mirela Iordan, country manager of Pfizer, who took the reins of the local subsidiary at the end of last year. She is the first Romanian in this job.
The clawback tax that the company pays grew at a faster rate than the revenue, going from RON68 million in 2016 to RON86 million this year, she added.
Most of the revenue of Pfizer in Romania comes from the reimbursements from the National Health Insurance House because most of the drugs it sells are on the list of subsidized drugs.
In Romania, Pfizer owns nutritional supplement plant Ferrosan in Cluj, which it bought in 2011. That company had a presence in Denmark, but Pfizer closed it and only kept the plant in Cluj, which makes probiotic supplements.
“A priority for Pfizer for next year is to continue the local initiatives of this year, especially by developing the logistics service hub in Bucharest. The hub is currently operational, with a team of ten people, and serves our Pfizer coworkers in the Iberic Peninsula and the Nordic countries. The plan is to continue expanding our team to attain the goal of having 40 positions filled by the end of 2018.” (EUR1=RON4.6400)
(English version by Loredana Fratila-Cristescu)